Literature DB >> 23852799

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

Sean M McBride1, S Michael Rothenberg, William C Faquin, Annie W Chan, John R Clark, Leif W Ellisen, Lori J Wirth.   

Abstract

BACKGROUND: With prior studies having looked at unselected cohorts, we sought to explore the mutational landscape in a high-risk group of head and neck squamous cell carcinoma (HNSCC) tumors.
METHODS: A multiplexed polymerase chain reaction (PCR) assay evaluating 68 loci in 15 genes was performed on 64 patients with high-risk HNSCC. Because of the frequent PIK3CA and AKT1 mutations in patients with oropharyngeal carcinoma, we evaluated the relationship between mutation status and both clinical/pathologic variables and tumor control in this subgroup.
RESULTS: Seventeen of 64 patients harbored mutations in the assayed loci: 16% in PIK3CA, 9% in TP53, 2% in AKT1, and 2% in epidermal growth factor receptor (EGFR). The frequency of PIK3CA/AKT1 mutations in oropharyngeal and sinonasal primaries was increased compared to other primary sites (35% vs 6%; p = .005). There was no relationship between mutation status and overall survival (OS), disease-specific death, or progression in the oropharyngeal cohort.
CONCLUSION: We identified frequent PIK3CA mutations in patients with high-risk HNSCC confined predominantly to the oropharyngeal and sinonasal subsites; for the first time, mutation in AKT1 has been identified in HNSCC.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  PIK3CA; high-risk; mutations; oropharyngeal; sinus; squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 23852799      PMCID: PMC4096067          DOI: 10.1002/hed.23430

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  28 in total

1.  An activating mutation in AKT1 in human prostate cancer.

Authors:  Joost L Boormans; Karin G Hermans; Geert J L H van Leenders; Jan Trapman; Paul C M S Verhagen
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

2.  Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer.

Authors:  Ziwei Yu; Paul M Weinberger; Clarence Sasaki; Brian L Egleston; William F Speier; Bruce Haffty; Diane Kowalski; Robert Camp; David Rimm; Eleftherios Vairaktaris; Barbara Burtness; Amanda Psyrri
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

3.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

4.  Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma.

Authors:  X Shao; R Tandon; G Samara; H Kanki; H Yano; L G Close; R Parsons; T Sato
Journal:  Int J Cancer       Date:  1998-08-31       Impact factor: 7.396

5.  Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.

Authors:  Avaniyapuram Kannan Murugan; Nguyen Thi Hong; Yasuhisa Fukui; Arasambattu Kannan Munirajan; Nobuo Tsuchida
Journal:  Int J Oncol       Date:  2008-01       Impact factor: 5.650

Review 6.  Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.

Authors:  Johan Bussink; Albert J van der Kogel; Johannes H A M Kaanders
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

7.  Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung.

Authors:  Donatella Malanga; Marianna Scrima; Carmela De Marco; Fernanda Fabiani; Nicla De Rosa; Silvia De Gisi; Natalia Malara; Rocco Savino; Gaetano Rocco; Gennaro Chiappetta; Renato Franco; Virginia Tirino; Giuseppe Pirozzi; Giuseppe Viglietto
Journal:  Cell Cycle       Date:  2007-12-26       Impact factor: 4.534

8.  Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.

Authors:  Irina Fenic; Klaus Steger; Christin Gruber; Christoph Arens; Joachim Woenckhaus
Journal:  Oncol Rep       Date:  2007-07       Impact factor: 3.906

9.  Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.

Authors:  Juana Maria Garcia Pedrero; Dario Garcia Carracedo; Cristina Muñoz Pinto; Agustín Herrero Zapatero; Juan Pablo Rodrigo; Carlos Suarez Nieto; Maria Victoria Gonzalez
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

10.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Authors:  John D Carpten; Andrew L Faber; Candice Horn; Gregory P Donoho; Stephen L Briggs; Christiane M Robbins; Galen Hostetter; Sophie Boguslawski; Tracy Y Moses; Stephanie Savage; Mark Uhlik; Aimin Lin; Jian Du; Yue-Wei Qian; Douglas J Zeckner; Greg Tucker-Kellogg; Jeffrey Touchman; Ketan Patel; Spyro Mousses; Michael Bittner; Richard Schevitz; Mei-Huei T Lai; Kerry L Blanchard; James E Thomas
Journal:  Nature       Date:  2007-07-04       Impact factor: 69.504

View more
  11 in total

Review 1.  Prevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.

Authors:  Christos Perisanidis
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

2.  Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.

Authors:  Nabil F Saba; Malania Wilson; Gregory Doho; Juliana DaSilva; R Benjamin Isett; Scott Newman; Zhuo Georgia Chen; Kelly Magliocca; Michael R Rossi
Journal:  Head Neck Pathol       Date:  2014-09-19

3.  Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.

Authors:  Daniel L Faden; Fernando Concha-Benavente; Anish B Chakka; Elizabeth L McMichael; Uma Chandran; Robert L Ferris
Journal:  Head Neck       Date:  2019-03-04       Impact factor: 3.147

Review 4.  Oncogenic growth factor signaling mediating tumor escape from cellular immunity.

Authors:  Fernando Concha-Benavente; Robert L Ferris
Journal:  Curr Opin Immunol       Date:  2017-02-14       Impact factor: 7.486

Review 5.  Unraveling cancer lineage drivers in squamous cell carcinomas.

Authors:  Yinglu Guan; Guan Wang; Danielle Fails; Priyadharsini Nagarajan; Yejing Ge
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

6.  Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

Authors:  Fernando Concha-Benavente; Raghvendra M Srivastava; Sumita Trivedi; Yu Lei; Uma Chandran; Raja R Seethala; Gordon J Freeman; Robert L Ferris
Journal:  Cancer Res       Date:  2015-12-16       Impact factor: 12.701

7.  Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.

Authors:  Shu-Jen Chen; Hsuan Liu; Chun-Ta Liao; Po-Jung Huang; Yi Huang; An Hsu; Petrus Tang; Yu-Sun Chang; Hua-Chien Chen; Tzu-Chen Yen
Journal:  Oncotarget       Date:  2015-07-20

8.  Clinical effects of p53 overexpression in squamous cell carcinoma of the sinonasal tract: A systematic meta-analysis with PRISMA guidelines.

Authors:  Xiaowei Wang; Wei Lv; Fang Qi; Zhiqiang Gao; Hua Yang; Weiqing Wang; Yali Gao
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 9.  Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.

Authors:  Fernando Concha-Benavente; Robert L Ferris
Journal:  Front Pharmacol       Date:  2017-05-30       Impact factor: 5.810

10.  Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.

Authors:  Darío García-Carracedo; Maria Ángeles Villaronga; Saúl Álvarez-Teijeiro; Francisco Hermida-Prado; Iñigo Santamaría; Eva Allonca; Laura Suárez-Fernández; Maria Victoria Gonzalez; Milagros Balbín; Aurora Astudillo; Pablo Martínez-Camblor; Gloria H Su; Juan Pablo Rodrigo; Juana María García-Pedrero
Journal:  Oncotarget       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.